Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 19, 2006, Pages 5157-5163

  Chung, Da Eun ^a   Kratz, Felix ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DOXORUBICIN; PRODRUG; UROKINASE RECEPTOR; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; MOUSE; NONHUMAN; PROTEIN BINDING; SOLUBILITY; SYNTHESIS;

ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; PRODRUGS; PROTEIN BINDING; SERUM ALBUMIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY PLASMINOGEN ACTIVATOR;

EID: 33747339731     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.023     Document Type: Article

References (32)

1. Andreasen P.A., Egelund R., and Petersen H.H. Cell Mol. Life Sci. 57 (2000) 25
2. Duffy M.J., and O'Grady P. Eur. J. Cancer Clin. Oncol. 20 (1984) 577
3. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Hofler H., Janicke F., and Graeff H. Thromb. Haemost. 78 (1997) 285
4. Schmitt M., Kanayama N., Janicke F., Hafter R., and Graeff H. Adv. Exp. Med. Biol. 297 (1991) 111
5. Ruppert C., Ehrenforth S., Scharrer I., and Halberstadt E. Cancer Detect. Prev. 21 (1997) 452
6. Chambers S.K., Gertz Jr. R.E., Ivins C.M., and Kacinski B.M. Cancer 75 (1995) 1627
7. Kuhn W., Schmalfeldt B., Reuning U., Pache L., Berger U., Ulm K., Harbeck N., Spathe K., Dettmar P., Hofler H., Janicke F., Schmitt M., and Graeff H. Br. J. Cancer 79 (1999) 1746
8. Kobayashi H., Fujishiro S., and Terao T. Cancer Res. 54 (1994) 6539
9. Steinmetzer T.I. Drugs 6 (2003) 138
10. Kratz F., Warnecke A., Schmid B., Chung D.E., and Gitzel M. Curr. Med. Chem. 13 (2006) 477
11. Kratz F., Warnecke A., Scheuermann K., Stockmar C., Schwab J., Lazar P., Drückes P., Esser N., Drevs J., Rognan D., Bissantz C., Hinderling C., Folkers G., Fichtner I., and Unger C. J. Med. Chem. 45 (2002) 5523
12. Kratz F., Drevs J., Bing G., Stockmar C., Scheuermann K., Lazar P., and Unger C. Bioorg. Med. Chem. Lett. 11 (2001) 2001
13. Mansour A.M., Drevs J., Esser N., Hamada F.M., Badary O.A., Unger C., Fichtner I., and Kratz F. Cancer Res. 63 (2003) 4062
14. Kratz F., Mansour A., Soltau J., Warnecke A., Fichtner I., Unger C., and Drevs J. Arch. Pharm. 338 (2005) 462
15. Kratz F., and Beyer U. Drug Deliv. 5 (1998) 1
16. Unger C., Medinger M., Steinbild S., Drevs J., and Häring B. German Cancer Congress, Berlin (2006)
17. Dubowchik G.M., and Firestone R.A. Bioorg. Med. Chem. Lett. 8 (1998) 3341
18. Masquelier M., Baurain R., and Trouet A. J. Med. Chem. 23 (1980) 1166
19. +, HPLC (495 nm): >95%.
20. 2, pH 5.0, containing 0.1% Brij 35). Homogenization was carried out with a micro-dismemberator at 3000 rpm for 3 min with the aid of glass balls, and the samples were then centrifuged at 5000 rpm for 10 min and kept frozen at -78 °C prior to use.
21. HPLC was performed with a BioLogic Duo Flow System from Bio-Rad (Munich, Germany), which was connected with a Merck F-1050 Fluorescence Spectrophotometer (EX. 490 nm, EM. 540 nm) and a Lambda 1000 visible detector from Bischoff (at λ = 495 nm); UV-detection at 280 nm; column: Waters, 300 Å, Symmetry C18 (4.6 × 250 mm) with precolumn; injection volume: 50 μL.
22. 3CN, 30% 4 mM sodium phosphate buffer (pH 3.0); gradient: 0-25 min 100% mobile phase A; 25-40 min increase to mobile phase B; 40-50 min 100% mobile phase B; 50-60 min decrease to initial mobile phase.
23. Werle B., Ebert W., Klein W., and Spiess E. Anticancer Res. 14 (1994) 1169
24. Duffy M.J., Blaser J., Duggan C., McDermott E., O'Higgins N., Fennelly J.J., and Tschesche H. Br. J. Cancer 71 (1995) 1025
25. Walker B., and Elmore D.T. Thromb. Res. 34 (1984) 103
26. O'Donnell-Tormey J., and Quigley J.P. Proc. Natl. Acad. Sci. U.S.A. 80 (1983) 344
27. Zimmerman M., Quigley J.P., Ashe B., Dorn C., Goldfarb R., and Troll W. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 750
28. Kurtzhals P., Larsen C., Hansen S., Aasmul-Olsen S., and Widmer F. Acta. Pharm. Nord. 1 (1989) 269
29. +.
30. 3CN, 30% 20 mM potassium phosphate (pH 7.0); gradient: 0-25 min 100% mobile phase A; 25-40 min increase to mobile phase B; 40-50 min 100% mobile phase B; 50-60 min decrease to initial mobile phase.
31. -1]. The concentration of 1 in the conjugate was adjusted to 500 ± 50 μM by concentrating the sample with CENTRIPREP-10-concentrators from Amicon, FRG (4 °C and 4500 rpm). Samples were kept frozen at -20 °C and thawed prior to use.
32. In vivo experiment. For the orientating toxicity study of 1 two female NMRI: nude mice were used. Compound 1 was dissolved in 10 mM sodium phosphate/5% d-glucose buffer, pH 7.0, and was administered at a dose of 3 × 59.95 mg/kg (3 × 24 mg/kg doxorubicin equivalents) by intravenous application to two animals with an interval of 7 days (1th, 8th, and 15th day).